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ABOUT THE COVER

The logo of West Allis Memorial Hospital (the shaded
area of the desigo 00 the cover) was choseo in the late
1960’s from the many submitted by the now defunct E.F.
T put down in print, in the
Schmidt Printing Compeny.
1966 Cancer Program Annual Report, the extended meaning
hefore the memory was lost.
“The bottom half is a stylized M, which stands for
Memorial dedicated to the memory of those who served in
It is also s symbol of the broad base of
our wars.
cosrunity support; the foundation, if you will, upon
which the hospital was built and continues to flour
ish. The upper half is a N and, with the central spire
Together,
representing an A, stands for West Allis.
The
then, it is West Allis Memorial: but it is more.
upper gracious concave is chalice—like, signifying the
fulinesa of the offering; the gift this hospital was
meant to be. The central spire signifies the desire for
excellence that is central to our mission.
These are the elements that are in our Cancer Program.
The broad base of support is in the conenunity, as well
as the enthusiasm of the medical and paramedical
personnel.
laboratory, radio
Nursing, dietary, rehah services,
administration,
records,
medical
pharmacy,
logy,
volunteers, and medical library services provide the
broad base on which our search for excellence in patient
The sharp point of the spire represents
care stands.

the cutting edge of technology and the constant
reaaaessment of what constitutes excellent care. Tt is
this constant reassessment that ia the heart of intel
Perhaps most
lectual curiosity and professionalism.
important to the Cancer Program is the “chalice” portion
In appreciation of the awesome problems
of the logo.
the patient with cancer confronts, it is this that we
Tnto this is poured our knowledge, our
have to offer.
Let’s try to
skills, our compassion, our conmitment.
see that this cup “runneth over”.
In 1968 the Cancer Comittee created the design for the
cover of the Annual Cancer Program Report which was
illustrated by hospital employee, Jeri Jende. The crah
which is the universal symbol for cancer and the sword
which is symbolic of the fight against cancer were added
to the hospital logo. This design symbolizes, in addi
tion to the above, the underlying cosisitment of West
Allis Memorial to the fight against cancer.

Daniel P. Collins, M.D.
Cancer Comittee Chairman
1985-1992

CANCER COMMITTEE CHAIRMAN’S FOREWORD

diagnosis of cancer seen at West Allis Memorial
Hospital. It continues to surpass both lung and
breast cancer. Our hospital has remained
dedicated to the diagnosis and treatment of this
very common disease in our community. All
aspects of therapy for patients with prostate
cancer are available at West Allis.
As in the past we have continued to participate
in national studies monitoring the quality and
appropriateness of services provided to our
patients. The results from a review of cases of
invasive prostatic carcinoma diagnosed in 1 985
and 1991 form the backbone of this report.
Members of the disciplines of pathology, radi
oncology
urology
and
radiation
ology,
summarize current issues and controversies in
the management of patients with prostatic
carcinoma.
The care of the cancer patient remains the main
focus of activity for West Allis Memorial
Hospital. The multi-disciplinary team approach
provides the most up-to-date information
available to all patients seen within the
hospital. Treatment decisions are discussed by
the members of this team which provides for
deciding on the most effective treatment
method or methods for each patient. Our tumor
registry continues its excellent work in both the
short-term and long-term follow-up of patients
seen at West Allis Memorial Hospital. This
remains the backbone of our cancer program
providing us information on where we’ve been
and the expectations of where we’ll be in the
future.

Kevin J. Murray M.D., Chairman
This annual report marks the 1 5th anniversary
of the approval of the West Allis Memorial
Hospital Cancer Program by the American
College of Surgeons. As shown by the graph on
page 9, West Allis Memorial Hospital remains
extremely committed to the diagnosis and care
of cancer patients. While the majority of our
patients do come from the West Allis commun
ity, patients from all across the Milwaukee
metropolitan area use our facility for their
short-term and long-term cancer care.
As was shown for the first time last year,
prostate cancer remains the most common

i
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INTRODUCTION

cancer care. It is through educational outreach
programs in prevention, screening and early
detection that we can have the greatest impact
on the incidence of cancer. One of the main
goals is to be an educational resource to the
community. The hospital’s commitment to
cancer care is evident by its many achieve
ments, accreditations and its state-of-the-art
treatment and advanced technology. More
important, however, the commitment to cancer
care is evident in the continuum of compas
sionate care provided to all patients who enter
through our doors, their families, and to the
community that lies beyond.

The staff of West Allis Memorial understands
that cancer treatment involves more than just
caring for a disease it means caring for the
whole person. Every facet of cancer care
requires specialists to support and educate both
patients and their families and friends. It is the
goal of West Allis Memorial to not only meet
the patient’s physical needs but also their
emotional, psychological, and spiritual needs. In
order to meet that goal, program planning
involves not only the aspects of care related to
the physical treatment, but also a variety of
programs aimed at the non-physiologic aspects
of care. These programs include educational
meetings, support groups for cancer survivors
and families, and activities focused on selfimage and self-esteem.
-

The purpose of this report is to inform and to
document this hospital’s experience in cancer
control activities during 1992 to the physicians,
health professionals, and the community.

The entire multidisciplinary team also focuses
on the needs of the community relating to

ii
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CANCER COMMITTEE REPORT

Committee Responsibilities

Patient Care Evaluation Studies

The Cancer Committee is responsible for
establishing and maintaining the appropriate
administrative structure and surrounding
atmosphere to provide optimal patient care.
The Cancer Committee, under the chairman
ship of Kevin Murray, M.D., supervises and
maintains standards for the hospital’s oncology
services. In 1992 the Cancer Committee met
four times.

In 1992, the committee participated in the
American College of Surgeon’s prostate cancer
long and short-term studies. Some of the
results of these studies are included in this
report. In addition, follow-up investigations
were conducted for studies conducted in
previous years to monitor the effectiveness of
the problem solving activities. The results of
the studies are distributed to the committees
and departments that are involved in the
provision of care to these patients and may
have an interest in these results.

Educational Conferences
This year the Cancer Committee has accomp
lished organizing, conducting and evaluating
weekly educational and consultative cancer
conferences (tumor boards) that are hospitalwide, multidisciplinary, and patient-oriented.
In addition to the tumor boards, other cancerrelated educational programs were scheduled.

Screening Activities

One of the Cancer Committee’s ongoing pro
jects is to ensure that quality and appropriate
care is provided for all cancer patients. The
committee includes a liaison member of the
Quality Assessment department. The Cancer
Committee implements and ensures quality
improvement by following a documented
system of review. The review system includes
methods to identify problems, opportunities to
improve patient care, problem-solving steps,
actions taken, and follow-up until the problems
are corrected.

The hospital’s Mammography Screening Center
continued to offer low cost affordable
mammography to the community. Free
mammography screening was again offered to
all female hospital employees without insurance
coverage. From May through September a
prostate cancer screening clinic was conducted
for the members of the Healthy Connection.
During that time 616 men participated in the
screening. The screening consisted of a
Prostatic Specific Antigen (PSA) blood test and
a digital rectal examination by a volunteer
urologist. Educational materials about prostate
health were provided to all participants. The
results of the examination with recommenda
tions for course of action was sent to each
participant. The exam results and a copy of the
PSA report were also sent to their personal
physician.

Registry Supervision

Primary Prevention Activities

The committee serves as consultant and super
vises the Tumor Registry. Periodically the
committee conducts chart/abstract review to
monitor the quality of information collected by
the registry personnel.

Activities in this area during the year included
the smoking cessation program, nutritional
counseling and community education of
environmental hazards.

Quality Improvement

2
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TUMOR BOARD
Multidisciplinary Board

Cases Presented

The primary goal of the Tumor Board is to
improve the care of the cancer patient. The
initial evaluation and treatment decisions are
the most critical in the outcome of the patient
with cancer. Because cancer is a systemic ill
ness it can rarely be detected, diagnosed, and
adequately treated by one physician. The
Tumor Boards offer multidiscipline patientoriented conferences which are prospective in
nature. This ensures the patients’ access to
pretreatment consultative services of all
disciplines.

The Tumor Board generally follows a clinical
case presentation with participation from both
the attending physician and the local specialists
who share their expertise, based on their
experience, as well as the knowledge of current
literature and clinical trials available. A
complete presentation of medical history,
physical findings, clinical course, radiographic
studies and pathological findings is provided.
During 1 992 fifty Tumor Boards were held and
173 cases were presented. A Total of 1,893
persons were in attendance, which is an
average weekly attendance of 38 persons.
Physicians who wish to have a case presented
at Tumor Board may do so by calling the
histology lab or contacting one of the patholo
gists prior to the meeting. Meetings are held
every Friday at noon in meeting rooms A and B.

Continuing Education
Through attendance at Tumor Board physicians
can learn about the new diagnostic modalities,
changing patterns of treatment, new concepts
in cancer patient management, and be aware of
the clinical trials that are available locally.
Continuing education credits are offered for
attendance. Medical staff, students, health
professionals and other related personnel are
encouraged to attend.

New Equipment
A new projector for the pathology slides was
installed. This has resulted in a dramatic
improvement in the projection of the slides.

Continuing Medical Education Programs
In addition to the Tumor Board Conferences the following didactic Cancer Conferences were presented.
Date

Speaker

Title

1-14-92

Maury Berger, M.D.

Myeloproliferative Disorders

3-1 0-92

Arlene Braker, M.D.

Cancer Rehabilitation Focus on
Post Mastectomy Patient

4-7-92

Beth Erickson, M.D.

Brachytherapy in the Treatment
of Gynecologic Tumors

5-1 2-92

David Weissman, M.D.

The Present Day Integrated
Approach to the Management of
Cancer Pain

9-1-92

John Moulder, Ph.D.

Power Lines and Cancer

-
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TUMOR REGISTRY REPORT

Specialized Cancer Data System

that approved Cancer Programs maintain at
least a 90 percent follow-up rate. A patient is
considered lost-to-follow-up if no contact has
been obtained within 15 months. About 55
percent of the patients in the registry have
expired and 45 percent are under active followup. In 7992 a follow-up rate of 95 percent was
maintained. A high follow-up rate assures
meaningful end results reporting.

The Tumor Registry is a specialized cancer data
system designed for the collection, research,
management and analysis of data on all types
of cancer diagnosed and/or treated at West
Allis Memorial. The information collected not
only contains incidence data but also the
severity/extent of disease, demographic data,
treatment data, recurrence information, quality
of survival and lifetime follow-up information.
The registry contains data collected since the
the official start date of January 1, 1978.

Data Utilization
Statistical reports of cancer data enables
physicians who treat cancer patients to
evaluate the success of specific treatment
modalities as measured by the quality of the
length of survival. Fundamental research on the
epidemiology of cancer is initiated through the
use of the accumulated data. In Wisconsin
cancer is a reportable disease. Registry data are
electronically transferred to the central registry.
Twenty-one requests for registry data were
received in 1992. These requests were from
staff physicians, administration and for
research projects and publications. The registry
computer program was utilized to identity
patients with cancer for invitation to the Cancer
Survivors Day Celebration which was held in
the spring of 7992 in collaboration with several
other area hospitals. The registry printed and
mailed out 600 invitations to cancer survivors.
The Cancer Program Annual Report, which
includes registry data, is distributed to the
medical staff, hospital departments, and the
West Allis Health Department. Analysis of
registry data may point out positive or negative
trends in the hospital and can be used by
administration for resource planning.

Information Networks
The medical record is no longer the only source
of information about oncology patients and the
services they receive. With more treatment
being administered in the outpatient, office or
home setting an extensive network to obtain
information must be established to collect the
complete information. These networks include
physician offices, other hospital registries,
extended care facilities, home hospice
agencies, visiting nurse associations and public
agencies.
Continued Growth
In 1992, 1,030 new cases were accessioned
into the registry. This is a 23 percent increase
over the 7991 total. This addition brings the
number of cases in the registry to 9,779. In
1978, the first year of the registry, the number
of cases accessioned were 440. The 1992 total
is an increase of 234 percent in comparison to
the 1978 total. A graph displaying the
accession year distribution is contained in
another portion of this report.

Patient Care Evaluation Studies
In addition to the collection of all cancer patient
information, registry personnel collected the
data for the patient care evaluation studies
conducted by the Cancer Committee. Studies
completed in 1992 were the American College
of Surgeons studies including the 1984 and the
1990 Prostate Cancer studies and the follow-up
data collection of previous studies of Melanoma
and Adriamycin and Stomach Cancer.

Lifetime Patient Follow-up
Lifetime follow-up is an important function of
the registry. This annual follow-up not only
provides current data on the status of each
patient, but also serves as a reminder to the
attending physician which patients are due for
follow-up examination. The American College
of Surgeons,Commission on Cancer requires
4

Other Activities

Organizational Activities

Registry personnel serve as staff to the Cancer
Committee. Minutes and attendance of the
Tumor Board Conferences are recorded by
registry personnel each week. In an effort to
upgrade the tumor registry computer program
to meet new Cancer Program requirements, 4
registry computer programs were evaluated.
Beginning with the 1992 cases, all new
accessions were coded using the new
International Classification of Diseases for
Oncology, second edition (ICD-O-2) coding
manual. The annual report is compiled by
registry personnel, with contributions from staff
physicians, under the direction of the Cancer
Committee.

The Tumor Registry staff are active participants
in the Wisconsin Tumor Registrar’s Associaton
(WTRA), the National Tumor Registrar’s Assoc
iation (NTRA) and the American Cancer Soci
ety CACS). Ms. Eckert is currently serving on
the ACS Southeastern District of Wisconsin,
Professional Education Committee and is
serving as President of WTRA. Ms. Miller is
currently serving as chairman of the
Membership Committee of WTRA. The Tumor
Registry staff strives to develop a working
relationship with organizations that care for
the cancer patient.

Confidentiality

The registry staff welcomes inquiries and the
opportunity to assist medical staff members to
retrieve data for special studies, audits,
research or personal information, Inquiries can
be made by contacting registry staff.

Inquiries Welcomed

Confidentialty rules concerning patient and
physician identities and related medical
information are strictly observed. Only group
data are analyzed and published.

Priscilla Eckert, ART, CTR
Sharon Miller
Telephone 328-71 22
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CANCER PROGRAM COMPONENTS
Oncology Unit

Rehabilitation Services

The inpatient Oncology Unit is a 30-bed unit
dedicated to the quality care of the cancer
patient. The unit is staffed with specialtytrained oncology nurses. These nurses have
specialized in the care of cancer patients and
their clinical experience and knowledge are
impressive. Participating with the nursing staff
in patient care are pharmacists, dietitians and
other professionals.

The coordinated team approach by the
physical, occupational and speech therapists
enables attainment of patient treatment goals.
The goal of this team of rehabilitation
specialists is to return each individual patient to
the highest level of function possible from
deficiencies induced by disease or treatment
and to teach relaxation techniques for the
management of anxiety, pain and nausea.

Patient education is a major responsibility of
the multidisciplinary team. Various educational
tools, handouts, videotapes, and teaching kits
are developed and revised as educational needs
or products develop.

Community Outreach
When cancer patients leave the direct care of
the hospital the network of support and caring
that was offered to them in the hospital is
extended out into the community. This network
is extended not to just the cancer patients and
their families, but to all patients and the
community as a whole.

Outpatient Oncology Clinic
The outpatient Oncology Unit can accom
modate up to 40 patients. Medical oncologists
see and treat their patients in the outpatient
clinic. Chemotherapy is a frequently used
modality for the treatment of cancer. Although
some regimens of chemotherapy require hospit
alization, the majority can be given on an out
patient basis. Therapists also may offer cancer
patients the opportunity to participate in clinic
trials.

Home care services are arranged including
everything from nursing to nutrition to equip
ment and therapy.
Meals Ala Wheels consists of the delivery of
nourishing appetizing meals by volunteers. This
program has been in existence since 1967.

Outpatient Surgery

Home visit services offers a wide variety of
laboratory and diagnostic services, 24 hours a
day, 7 days a week.

The outpatient surgery unit is equipped on a 24
hour basis to handle all patients’ needs. Under
normal circumstances, outpatients are able to
go home following surgery. However, outpat
ients are invited to stay up to 24 hours at no
additional cost.

Respite care may be utilized by patients who
are medically discharged from the hospital, but
who prefer to stay where there is 24 hour
nursing service and complete care.
Support Groups

Radiation Oncology
A support group for Caregivers meets at West
Allis Memorial. Many people have become a
caregiver for someone who needs extra
support. The opportunity to share ideas and to
learn new things with other caregivers can be
helpful.

The Radiation Oncology division of the Radi
ology Department offers the cancer patient
external beam therapy, interstitial and intra
cavity brachytherapy. Radiation therapists offer
cancer patients the opportunity to participate in
national treatment protocols.

6

cussions.

American Cancer Society Reach-to-Recovery
program volunteers provide rehabilitation
support for women who have had mastect
omies.

Positive People is a unique support group
offered by West Allis Memorial. Oncology
nurses, who are committed to helping people
understand and cope with their disease,
facilitate the meetings. The meetings are
informal and include guest speakers about
chemotherapy, radiation therapy, nutrition, etc.
Positive People provides the opportunity for
individual and group experiences with those in
a similar situation.

I Can Cope is a patient education program
offered by the hospital in conjunction with the
American Cancer Society. Living with cancer
can be one of the hardest challenges anyone
faces. I Can Cope helps cancer patients meet
this challenge by clarifying cancer facts and
myths, providing encouragement and practical
hints through presentations and class dis
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1992 CANCER CASES
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cases accessioned in 1992. Breast cancer
incidence remained about the same when
compared to last year. There were 30 more
lung cancer cases in 1992 when compared to
1991; this represents a 28 percent increase.
The number of colon cancer cases doubled in
1992 to 81 from 41 cases in 1991. The other
sites remained about the same as last year. Of
the 1030 cases, 965 were analytic cases and
65 were non-analytic cases

There has been a steady increase over the
years in the cancer cases accessioned in the
registry. In 1992 there was an increase of 194
cases. For the first time there were more men
diagnosed with cancer than women. This was
apparently due to the large increase in prostate
cancer cases. This increase is probably
artifactual because of the prostate cancer
screening. Prostate cancer was 41 percent of
the male cancers accessioned in 1 992, and
represented more than 22 percent of the total
9
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SITE TABULATION FOR 1992 CANCER CASES
SITE
ORALCAVITY

TOTAL CASES

MALE

FEMALE

23

(2.20%)

11

(2.0%)

12

(2.6%)

PHARYNX

5

(0.47%)

3

(0.5%)

2

(0.4%)

ESOPHAGUS

8

(0.77%)

5

(0.9%)

3

(0.6%)

STOMACH

13

(1.26%)

5

(0.9%)

8

(1.7%)

SMALL INTESTINE

4

(0.38%)

1

(2.2%)

3

(0.6%)

COLON

81

(7.85%)

45

(8.0%)

36

(7.7%)

RECTUM & ANUS

26

(2.52%)

15

(2.7%)

11

(2.4%)

LIVER & BILIARY TRACT

7

(0.67%)

4

(0.7%)

3

(0.6%)

GALLBLADDER

1

(0.09%)

0

(0.0%)

1

(0.2%)

PANCREAS

19

(1.84%)

9

(1.6%)

10

(2.1%)

LARYNX

13

(1.26%)

9

(1.6%)

4

(0.9%)

BRONCHUS & LUNG

136 (13.20%)

85 (15.1%)

51 (10.9%)

MEDIASTINUM & PLEURA

2

(0.19%)

2

(0.4%)

0

(0.0%)

BONE, JOINTS, CARTILAGE

1

(0.09%)

1

(0.2%)

0

(0.0%)

BLOOD & BONE MARROW

31

(3.00%)

22

(3.9%)

9

(1.9%)

SKIN

26

(2.52%)

15

(2.7%)

11

(2.4%)

4

(0.38%)

2

(0.4%)

2

(0.4%)

1

(0.2%)

CONNECTIVE,SOFT TISSUE
BREAST

142 (13.78%)

141 (30.3%)

VULVA

7

(0.67%)

0

(0.0%)

7

(1.5%)

VAGINA

1

(0.09%)

0

(0.0%)

1

(0.2%)

CERVIX UTERI

44

(4.27%)

0

(0.0%)

44

(9.4%)

CORPUS UTERI

34

(3.30%)

0

(0.0%)

34

(7.3%)

OVARY

17

(1.65%)

0

(0.0%)

17

(3.6%)

0

(0.0%)

PROSTATE GLAND

232 (22.52%)

232 (41.1%)

TESTIS

9

(0.87%)

9

(1.6%)

0

(0.0%)

KIDNEY

19

(1.84%)

14

(2.5%)

5

(1.1%)

URETER

1

(0.09%)

0

(0.0%)

1

(0.2%)

44

(4.27%)

36

(6.4%)

8

(1.7%)

EYE & ADNEXA

2

(0.19%)

1

(0.2%)

1

(0.2%)

BRAIN

12

(1.16%)

6

(1.1%)

6

(1.3%)

OTHER NERVOUS SYSTEM

1

(0.09%)

1

(0.2%)

0

(0.0%)

THYROID GLAND

9

(0.87%)

1

(0.2%)

8

(1.7%)

LYMPH NODES

30

(2.91%)

16

(2.8%)

14

(3.0%)

UNKNOWN PRIMARY

26

(2.52%)

13

(2.3%)

13

(2.8%)

URINARY BLADDER

TOTAL CASES

1030

564 (100.0%)

(100.0%)

10

466 (100.0%)

4,

r

PROSTATE CANCER
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IMAGING IN PROSTATE CANCER
By Allan Van Nostrand M.D.

This will be discussed in a separate presenta
tion.
The primary diagnostic imaging modalities used
in staging of cancer of the prostate are bone
scanning and computed tomography (CT). The
bone scan is the most sensitive test for detect
ing clinically occult metastatic bone lesions.
CT or magnetic resonance imaging (MRI) can
demonstrate a much wider variety of findings
including extension of prostate carcinoma
outside the prostatic capsule, extension of
disease to the pelvic sidewalls, pelvic and
retroperitoneal lymphadenopathy, and hepatic
metastases. CT and MRI cannot demonstrate
microscopic nodal metastases which have not
caused lymph node enlargement. Pelvic
lymphadenectomy at the time of surgery is
performed to evaluate the lymph nodes for
microscopic tumor metastases. Demonstration
of more advanced disease than is clinically
apparent has importance for the type and
extent of treatment.

Allan Van Nostrand M.D.

Diagnostic imaging of the prostate is useful for
staging of cancer of the prostate as well as
monitoring the patient following treatment.
Screening for prostate cancer is performed
primarily by digital rectal examination. There is
an important role for transrectal ultrasound in
screening as well as staging of prostate cancer.

Bone scanning and CT are also useful in
monitoring the effectiveness of therapy for
prostate cancer. The ability to demonstrate
recurrent or metastatic disease affects the
course and nature of continued treatment.
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Figure 1

MRI of pelvis prostate gland (A)
normal anatomy

Figure 2

MRI of pelvis (coronal view)
prostate gland (A) normal anatomy

-
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Figure 1

-

-
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Figure 2

A
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-

Prostate gland

Figure 3

MRI of pelvis cancer beginning to
spread outside of the capsule of the
prostate into the periprostatic fat
tD)
-

Figure 3

Figure 4

CT scan of pelvis prostate is
irregularly enlarged. Cancer
extending outside the prostatic
capsule.
-

KEY
A

Figure 4
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-

Prostate gland

Figure 5

CT scan of pelvis enlarged seminal
vesicles (B). Prostate cancer has
invaded these structures growing
directly from the prostate

Figure 6

CT scan of pelvis enlarged iliac
lymph nodes (C). Prostate cancer
has metastasized to those nodes.

-

Figure 5

-
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Figure 6

16

Prostate gland

-

enlarged seminal vesicles

-

enlarged iliac lymph nodes

-

-

extension of prostate cancer outside the
prostate capsule
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PROSTATIC SCREENING PROGRAM AT WEST ALLIS MEMORIAL
By Christopher K. Kubat, M.D.

prostate carcinoma is the differential. One
commonly asked question is, “Why can’t one
rely solely on the PSA or the digital rectal exam
This answer
rather than both modalities?
involves the fact that the two tests are compli
mentary and each have their own inherent false
negative rates. In addition, these two tests do
not always detect the same cancers. In using
both modalities, one can detect up to 78 per
cent more organ-confined carcinomas. There
fore, in using both tests, most significant
prostate carcinomas will be diagnosed.
“.

West Allis Memorial Hospital has been quite
involved in prostatic screening for the purpose
of early detection. From May 8, 1992 through
September 30, 1992, 1 8 clinics were
conducted and 616 men were screened. This
consisted of serum PSA blood test and a rectal
examination by a volunteer urologist. Of these
61 6 individuals, 28 percent of the screened
population, namely 170 individuals, had abnor
mal findings. This consisted of 9 percent
having solely an abnormality in the serum PSA,
20 percent having both an abnormal digital
rectal exam and an abnormal PSA, and 47
percent noting an abnormal rectal exam with a
normal PSA. In addition, 23 percent were noted
to have an abnormal PSA along with benign
enlargement of the prostate. These abnor
malities were also age-dependent which goes
along with the natural history of prostatic
disease in general. Of these individuals, 93
percent did seek medical follow-up. Of these
persons screened, 1 5 had definitive therapy for
their prostate carcinoma, namely, 8 having
surgery and 7 undergoing radiation therapy. It
should again be stressed that prostate cancer is
number two in cancer deaths and the mortality
rate can be decreased, thus early detection is
crucial.

Christopher K. Kubat, M.D.

In the United States, carcinoma of the prostate
is the most common cause of cancer deaths in
males, If the mortality rate as it relates to
prostate carcinoma is to be reduced, it will
require detection of cancer when it is still
and instituting definitive
organ-confined,
therapy, either surgery or radiation therapy.
Therefore, the goal of prostate screening is in
early detection.
The two front line tests in screening involve the
prostatic specific antigen, otherwise known as
PSA, and the digital rectal exam. The American
College of Radiology advocate that these two
modalities are indicated yearly in men 50 years
of age or older and in younger men in the
higher risk groups.
The PSA is a serine protease produced by the
prostatic tissue and normally very little is
present in the general circulation. When this
level is abnormal (greater than 4.0 ng), then

Programs such as the prostatic cancer screen
ing program at West Allis Memorial Hospital are
designed to address this specific issue.
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THE DIAGNOSIS AND SURGICAL THERAPY OF PROSTATE CANCER
By Christopher K. Kubat, M.D.

Prostatic carcinoma represents the most
common malignancy in males and is the
number two cause of cancer deaths in the
United States. Early detection is vital in
attempts at diagnosing localized carcinoma so
definitive therapy, either surgery or radiation
therapy, can be instituted. The diagnosis of
prostate carcinoma involves first performing
two complimentary tests, the serum PSA and
the digital rectal examination. The American
Urological Association, the American Cancer
Society, and the American College of Radiology
recommend these two modalities yearly for
men ages 50 years or older and younger males
in higher risk groups.

transfused blood and the risk of erectile dys
function and urinary incontinence. Surgery to
remove the prostate first involves performing a
pelvic lymphadenectomy which usually involves
a limited dissection, ie., nodes from the
obturator fossa. This can be done at the time of
open surgery. However, again due to the mod
ern surgical advances, these can be removed
laparoscopically. However, this is done usually
when the PSA approaches or exceeds 30.0 ng
due to the infrequent occurrence of positive
nodes with a lower level. The surgery then
involves removing the prostate, the seminal
vesicles, and part of the vas deferens. This is
performed along with sparing of the neuro
vascular bundle in the appropriate candidates.

The PSA (prostatic specific antigen) is a serine
protease produced by prostatic cells, and, in
general, are in low quantities in the general
circulation. It is well known that with prostatic
carcinoma, the PSA level will progressively rise.
If the patient exhibits an abnormal PSA (greater
than 4.0 ng) or has an abnormal rectal exam,
further studies are warranted. The transrectal
prostate ultrasound initially thought to have a
possible role in screening is now reserved for
patients who exhibit an abnormal PSA or digital
rectal exam, or both. This is a painless modality
used for accurately and precisely directing
needle biopsies and affording staging informa
tion.

Surgery is carried out in an attempt to cure one
of his prostate carcinoma. Evidence from longterm follow-up indicates that this has achieved
regularity in those with negative surgical
margins. Although there is up to 60 percent
surgical upstaging in some studies, other
studies confirm that with proper staging and
patient selection, extracapsular extension or
positive surgical margins are unlikely. A five
year survival rate in these patients in reviewing
the literature ranges from 75 percent to in
excess of 90 percent, a 10 year survival rate
ranges from 50 percent to 80 percent, and a
1 5 year survival rate ranges from 35 percent to
62 percent.

The criteria for clinically localized prostate
carcinoma include a normal transrectal prostate
ultrasound, a normal bone scan, and frequently
a CT scan of the pelvis. If clinically localized
prostate carcinoma is diagnosed, then definitive
therapy can be employed. Due to modern surgi
cal advances and better knowledge of the blood
and nerve supply to the prostate, surgery is
more acceptable due to the reduced need for

Again, early detection is crucial, and West Allis
Memorial Hospital is in the forefront in this
endeavor. One can only surmise that if the
mortality rate can be decreased by prostate
cancer which is the number two cause of
cancer deaths in the United States, then early
detection is crucial.
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THE PROSTATE
ADENOCARCINOMA OF
RADIATION THERAPY
By Kevin J. Murray, M.D.

Kevin J. Murray, M.D.
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AMERICAN COLLEGE OF SURGEONS
PROSTATE CANCER STUDY RESULTS
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AMERICAN COLLEGE OF SURGEONS
PROSTATE CANCER STUDIES
TUMOR GRADE
1990 Study

1984 Study
This Hospital
#

DifferentiationlGrade

This Hospital
¾
#

All Hospitals
%
#

All Hospitals
¾
#

Well Differentiated, Grade I

8

32.0

4707

32.1

10

40.0

6352

27.6

Mod. Differentiated, Grade II

12

48.0

4760

32.5

11

44.0

9253

40.1

Poorly Differentiated, Grade III

3

12.0

3278

22.4

4

16.0

4871

21.1

Undifferentiated, Grade IV

0

0.0

356

2.4

0

0.0

388

1.7

Grade Unknown

2

8.0

1539

10.5

0

0.0

2145

9.3

Other Responses

0

0.0

26

0.2

0

0.0

44

0.2

1990 Study

1984 Study
Gleason’s Score

This Hospital
#

All Hospitals

This Hospital
%
#

All Hospitals
#

2

3

12.0

519

3.5

3

12.0

1034

4.5

3

0

0.0

636

4.3

0

0.0

1505

6.5

4

3

12.0

664

4.5

6

24.0

1867

8.1

5

4

16.0

851

5.8

5

20.0

2846

12.3

6

5

20.0

676

4.6

4

16.0

2240

9.7

7

2

8.0

945

6.4

3

12.0

2813

12.2

8

1

4.0

487

3.3

1

4.0

1187

5.1

9

1

4.0

404

2.8

2

8.0

893

3.9

10

0

0.0

86

0.6

0

0.0

209

0.9

Not reportedlunkn.

6

24.0

9146

62.4

1

4.0

7907

34.3

Other responses

0

0.0

252

1.7

0

0.0

552

2.4

21

1

I.

AMERICAN COLLEGE OF SURGEONS
PROSTATE CANCER STUDIES

Test Results
Prostatic Acid Phosphatase

1984 Study
This Hospital
#
¾

1990 Study

All Hospitals
#
¾

This Hospital
#
¾

All Hospitals
¾
#

Normal

17

68.0

5619

38.3

11

44.0

6793

29.5

Abnormallelevated

6

24.0

3533

24.1

5

20.0

4470

19.4

Test not donelunknown if done

2

8.0

5021

34.2

9

36.0

10797

46.8

Test done, results unknown

0

0.0

232

1.6

0

0.0

423

1.8

Other responses

0

0.0

261

1.8

0

0.0

570

2.5

lest Results
Prostatic Specific Antigen

1984 Study
This Hospital
#
¾

1990 Study

All Hospitals
#
¾

This Hospital
¾

All Hospitals
#
¾

Normal

0

0.0

271

1.8

4

16.0

3051

13.2

Ahnormallelevated

0

0.0

477

3.3

12

48.0

12275

53.2

25

100.0

13332

90.9

8

32.0

6811

29.5

Test done results unknown

0

0.0

100

0.7

1

0.4

471

2.0

Other responses

0

0.0

486

3.3

0

0.0

445

1.9

Test not donelunknown if done

Histologic tumor grade of adenocarcinoma of
the prostate is strongly correlated with
prognosis and response to treatment. Men with
low-grade (well-differentiated) tumors have a
relatively good prognosis, while those with
high-grade (anaplastic) tumors have a poor
prognosis. The tables on the opposite page
show that in this hospital there was a higher
percentage of cases with reported tumor grade,
both differentiation and Gleason’s score, than
the other hospitals in the studies. Once the
histologic diagnosis of prostate cancer has been
established, serum levels of PSA (Prostate-

Specific Antigen) and PAP (Prostatic Acid
Phosphatase) are measured to help determine
the stage of disease. Until recently, serum PAP
was the most useful biochemical marker for
monitoring patients with prostate cancer. There
is a clear correlation between elevated PAP
levels and the presence of metastatic disease.
Studies suggest that PSA is more sensitive than
PAP for detecting prostate cancer. The tables
above show the increase in the use of PSA in
1992 as compared to 1984 for all participants
in the study.
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AMERICAN COLLEGE OF SURGEONS
PROSTATE CANCER STUDIES
SURGICAL TREATMENT
1990 Study

1984 Study
TYPE OF SURGERY

All Hospitals
¾
#

This Hospital
#

This Hospital
¾

All Hospitals
%
#

No surgical procedure

0

0.0

531

3.6

0

0.0

995

4.1

lncisional, needle or aspiration
biopsy of other site

0

0.0

237

1.6

0

0.0

319

1.4

Biopsy of primary site

2

8.0

2923

19.9

9

36.0

5359

23.2

Exploratory only

0

0.0

15

0.1

0

0.0

42

0.2

Bypass surgery, ostomy only

0

0.0

0

0.0

0

0.0

3

0.0

Exploratory and biopsy

0

0.0

84

0.6

1

4.0

123

0.5

Bypass surgery, ostomy & biopsy

0

0.0

5

0.0

0

0.0

13

0.1

TURP or cryoprostatectomy wlo
nodes

15

60.0

8277

56.4

9

36.0

9219

40.0

TURP or cryoprostatectomy
wlnodes

2

8.0

270

1.8

0

0.0

227

1.0

Subtotal prostatectomy wlo
nodes

1

4.0

263

1.8

0

0.0

229

1.0

Subtotal prostatectomy w/nodes

0

0.0

41

0.3

0

0.0

72

0.3

Total prostatectomy wlo nodes

1

4.0

231

1.6

0

0.0

384

1.7

Total prostatectomy w/nodes

4

16.0

1077

7.3

5

20.0

5041

21.9

Cystoprostatectomy wlpelvic
exenteration

0

0.0

45

0.3

1

4.0

79

0.3

Surgery of regional &Ior distant
site(s)Inode(s)

0

0.0

451

3.1

0

0.0

629

2.7

Surgery, Not otherwise specified

0

0.0

70

0.5

0

0.0

63

0.3

Unknown it surgery done

0

0.0

23

0.2

0

0.0

30

0.1

Other responses

0

0.0

133

0.9

0

0.0

266

1.2
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AMERICAN CDLLEGE OF SURGEONS
PROSTATE CANCER STUDIES
1984 Study
Radiation Therapy plannedlgiven

This Hospital
II

Radiation Therapy given

1990 Study

All Hospitals
#
%

This Hospital
#

All Hospitals
#
%

7

28.0

4403

30.0

11

44.0

6662

28.9

Nolnot recommended

18

72.0

9280

64.6

14

56.0

14809

64.2

Patient refused radiation therapy

0

0.0

135

0.9

0

0.0

347

1.5

Radiation planned but not given
due to complication

0

0.0

42

0.3

0

0.0

100

0.4

Unknown

0

0.0

317

2.2

0

0.0

570

2.5

Other Responses

0

0.0

289

2.0

0

0.0

565

2.5

1984 Study
Hormone therapy plannedlgiven
Hormone therapy given

This Hospital
#
%

1990 Study

All Hospitals
#
¾

This Hospital
¾

All Hospitals
%
#

8

32.0

4503

30.7

4

16.0

5744

24.9

Nolnot recommended

17

68.0

8687

59.2

21

84.0

14825

64.3

Patient refused hormone therapy

0

0.0

98

0.7

0

0.0

234

1.0

Hormonal therapy planned, but
not given due to complications

0

0.0

26

0.2

0

0.0

54

0.2

Unknown

0

0.0

685

4.7

0

0.0

1049

4.6

Other responses

0

0.0

667

4.5

0

0.0

1147

5.0

TREATMENT OF PROSTATE CANCER
hospital. There was an increase in the use of
radiation therapy for the treatment of prostate
cancer in 1990 in this hospital whereas there
was a slight decrease evident in the other
hospitals. There was decreased use of hormone
therapy evident in all hospitals involved in the
studies. This is probably due to the fact that
prostate cancer was being diagnosed at an
earlier stage in 1990.

The tables on the opposite page show evidence
of a change in surgical treatment patterns for
prostate cancer for all hospitals in the studies.
There was a decrease in the TURP (transureth
ral prostatectomy) without nodal dissection in
1990 and an increase in the total prostatec
tomies with nodal dissection. TURP without
nodal dissection still remain the most common
surgical treatment for prostate cancer. Biopsy
only increased by 28 percent in 1990 at this
24

AMERICAN COLLEGE OF SURGEONS
PROSTATE CANCER STUDIES
SURVIVAL RESULTS
1984 STUDY

Patient and Cancer Status at
Last Contact

AN Hospitals

This Hospital
#

#

Alive, no evidence of prostate
cancer

9

36.0

3570

24.2

Alive, with prostate cancer

2

8.0

1515

10.3

Alive, prostate cancer status
unknown

0

0.0

1351

9.2

Dead, no evidence of prostate
cancer

7

28.0

1569

10.7

Dead, prostate cancer present at
death

7

28.0

5219

35.6

Dead, prostate cancer status
unknown

0

0.0

1356

9.2

Other response(s)

0

0.0

86

0.6
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WEST ALLIS MEMORIAL HOSPITAL
PROSTATE CANCER STATISTICS
1978- 1992

26

r

AMERICAN UROLOGIC SYSTEM STAGE DISTRIBUTION
PROSTATE CANCER
1992
STAGE C-i

STAGE C

STAGE 0-2

STAGE UNKNOWN
STAGE A-i

STAGE 8-2

STAGE A-2

B

STAGE B-i

American Urologic System Stage Grouping
Incidental Finding by Pathologist and Clinically Unsuspected
Stage A-i
Stage A-2

-

-

3 or less foci, well differentiated
Diffuse or more than 3 foci, poorly differentiated and more extensive than A-i

Clinically Palpable in the Prostate
Stage
Stage
Stage
Stage
Stage
Stage
Stage
Stage

Confined to the prostate, not otherwise specified
B
B-i Less than 2 cm involving one lobe
B-2 Greater than 2 cm, diffusely involved
Extension beyond the prostatic capsule, not otherwise specified
C
C-i Extension to periprostatic tissue
C-2 Extension to seminal vesicle(s)
D-i Involvement of the pelvic lymph nodes below the aortic bifurcation
sites
D-2 Lymph node involvement above the aortic bifurcation and/or distant metastases to other
-

-

-

-

-

-

-

-
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ACCESSION YEAR DISTRIBUTION
PROSTATE CANCER
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The incidence of prostate cancer at West Allis
Memorial gradually increased until 1991 and
1992 when there was a dramatic increase in
the number of cases accessioned. One factor
that has been responsible for this acceleration
is the increase in detection. More frequent use
of improved diagnostic methods, such as serum
testing, ultrasound, and transrectal ultrasound
guided needle biopsies may also contribute to
an increase in reported cases. In 1992 there
was a 61 percent increase in prostate cancer,
when compared to the cases in 1 991.

The graph on the opposite page displays the
American Urologic System stage at the time of
diagnosis of the prostate cancer cases
accessioned in 1992 at West Allis Memorial.
This staging system identifies the tumors that
were incidental findings (Stage A). Only 11
percent of the 232 cases were incidental
findings. Of the total cases accessioned, in 73
percent of the cases, the tumor was confined
to the prostate (Stages A and B). The number
of distant stage tumors (Stage D-2) has steadily
decreased over the years.
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PROSTATE CANCER AGE AT DIAGNOSIS
1978
AGE AT DIAGNOSIS

-

1992 ACCESSIONS

NUMBER OF PATIENTS

PERCENT OF CASES

40-49

7

1%

50-59

81

7%

69

344

29%

79

504

42%

89

240

20%

90-99

15

1%

60
70
80

-

-

-

1 992 ACCESSIONS
AGE AT DIAGNOSIS

NUMBER OF PATIENTS

PERCENT OF CASES

40-49

3

1%

50-59

12

5%

60-69

67

29%

70-79

110

47%

80-89

38

16%

90-99

2

1%

Cancer of the prostate is the most frequently
diagnosed cancer among men. It is the second
leading cause of cancer deaths among men,
Prostate cancer is
following lung cancer.
primarily a disease of older men. Age-specific
incidence rates show that prostate cancer is
rare in men under 59, but rapidly increases in
men over the age of 60
and peaks in the
70’s, as demonstrated in the graphs shown

above. In comparing all the prostate cancers in
the registry (1978- 1992 accessions) with the
1992 accessions the only appreciable differ
ence is the 5% increase in the 70 79 year age
group and the decrease of 4% in the 80 89
year age group of the 1992 accessions. This
would indicate earlier detection as a result of
the screening programs.
-

-
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SEER STAGE DISTRIBUTION
PROSTATE CANCER
1978

-

1992

REGIONAL BY DIRECT EXTENSION
REGIONAL LYMPH NODES
UNKNOWN
OTHER

DISTANT

LOCAL

GE
OLOGY AND END RESULTS (SEER) STA
CANCER SURVEILLANCE EPIDEMI

LOCAL
REGIONAL

DISTANT

UNSTAGED

organ of origin.
An invasive neoplasm confined to the
directly into
nd the limits of the organ of origin
A neoplasm that has extended beyo
nsion and
nal lymph nodes; or both direct exte
surrounding organs or tissues; into regio
regional lymph node involvement.
ary tumor either
ts of the body remote from the prim
A neoplasm that has spread to par
ous metastasis.
by direct extension or by discontinu
a stage.
Information is not sufficient to assign
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SEER STAGE DISTRIBUTION
PROSTATE CANCER
1992

REGIONAL BY DIRECT EXTENSION

OTHER

DISTANT

LOCAL

When comparing the stage at the time of
diagnosis of all the prostate cancer cases in the
tumor registry (see opposite page) with the
cases accessioned in 1992, it is apparent that
prostate cancer was being diagnosed at an
earlier stage in 1992. Particularly encouraging
is the decrease by one-half of the cases
diagnosed with distant stage cancer. Regional
stage has remained about the same.

The two percent increase in the regional by
direct extension stage in 1 992 is probably as a
result of the change in surgical treatment
patterns (demonstrated on the graphs on the
following pages). There was an increase in the
number of radical prostatectomies, which
would tend to up-stage the clinical staging by
demonstrating spread of the tumor beyond the
prostate capsule, not evident clinically.
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PROSTATE CANCER
197$- 1992
TREATMENT COMBINATIONS

Surgery & Hormones
Surgery & Radiation

Surgery, Radiation & Hormones
Other
Hormones
Surgery
None

Radiation & Hormones
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PROSTATE CANCER
1992
TREATMENT COMBINATIONS

Surgery
Surgery & Hormones
Surgery & Radiation

Hormones
Radiation & Hormones

None

Radiation

In comparing the treatment combinations
between all the prostate cancers cases in the
registry (see opposite page) with the treatment
combinations of 1992 (shown above), the most
obvious difference is the increase in radiation
therapy only. This would include patients with
biopsy only who were treated with radiation.
The percentage has doubled in this category.
The category of surgery contains both those

patients with transurethral resections as well as
simple and radical prostatectomies. The use of
hormone therapy decreased in 1992. This
decrease probably correlates with the decrease
in the number of patients with distant stage
disease at the time of diagnosis. There was an
increase in 1992 in the percentage of patients
receiving no treatment.
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PROSTATE CANCER
197$- 1992

SURGERY DISTRIBUTION

TURP wj nodes

Radical prostatectomy w/o nodes
Radical prostatectomy wi nodes

Prostatectomy, NOS
Other
Biopsy only

TURP wlo nodes

Key
TURP w/o nodes

Transurethral resection without regional lymph nodes

TURP w/nodes

Transurethral resection with regional lymph node dissection

Radical prostatectomy w/o nodes

Excision of the prostate, ductus deferens, and seminal vesicles
without regional node dissection

Radical prostatectomy w/nodes

Excision of the prostate, ductus deferens, and seminal vesicles
with regional node dissection

Prostatectomy, NOS

Prostatectomy, not otherwise specified (includes cases that had
surgery elsewhere and received adjuvant therapy here)

Other

Includes categories of less than one percent of the cases

Biopsy only

Did not have any surgical procedure

35

r

PROSTATE CANCER
1992
SURGERY DISTRIBUTION

Radical prostatectomy wI nodes

Other

Biopsy only

TURP wfo nodes

The graphs on this page and the opposite page
are breakdowns of the surgery category in the
treatment combinations for prostate cancer
illustrated on the previous pages. In comparing
the types of surgery performed for all prostate
cancer cases in the tumor registry with the
prostate cancer cases accessioned in 1 992,
there are some notable differences. Although
there was not a change in the percentage of
patients who were treated with surgery for

their prostate cancer, there was a significant
difference in the type of surgery performed.
There was a 30 percent decrease in the trans
urethral resections without regional lymph node
dissections and a 31 percent increase in radical
prostatectomies with regional lymph node
dissections. Biopsy only percentage mote than
doubled. This correlates with the increase in
radiation therapy only category on the previous
pages.
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PROSTATE CANCER
10 YEAR SURVIVAL BY STAGE*
1978

*

1992

YEAR

ALL STAGES

LOCAL

REGIONAL

DISTANT

1

91%

94%

95%

78%

78%

2

81%

87%

90%

56%

63%

3

72%

80%

84%

42%

56%

4

63%

72%

77%

30%

46%

5

54%

62%

67%

21%

38%

6

47%

56%

60%

16%

34%

7

41%

49%

50%

12%

34%

8

35%

42%

43%

11%

34%

9

32%

39%

35%

10%

29%

10

26%

31%

30%

9%

29%

SEER Summary staging system
Survival rate calculation by Actuarial (Life Table) Method
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UNKNOWN

GLOSSSARY

Accessioned

Entered into the Tumor Registry data base

ACOS

American College of Surgeons In 1932 the American Cancer Society
urged the American College of Surgeons to take the lead in setting guidelines
for cancer care. Approval of hospital-based cancer programs has been the
foundation for improving the quality of care of patients with cancer.

ACS

American Cancer Society

AJCC

American Joint Committee on Cancer
end results reporting

NCI

National Cancer Institute

PCE’s

Patient care evaluation studies Evaluation of cancer patient care
through the process of problem identification, problem analysis, action planning
and follow-up monitoring

SEER

Surveillance, Epidemiology and End Results program of National Cancer Institute

Stage of Disease

The extent of disease determined at the time of initial workup for the first
course of treatment

TNM Staging

AJCC classification to determine the extent of disease at the time of diagnostic
workup for the first course of treatment
T Size of tumor
N Nodal involvement
M Metastasis at distant sites

-

-

organized for cancer staging and

-

-

-

-

Treatment:
Surgery

Operative procedure to remove all or part of cancer tissue

Radiation

Cancer-directed internal or external radiation

Chemotherapy

Includes all chemotherapeutic agents other than hormones

Hormones

Includes administration of hormones, steroids and endocrine surgery

None

Cases with no report of definitive treatment
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